Analysis for BSX
- 📈 Growth — 28/30
- 💰 Profitability — 17/20
- 🏦 Financial Health — 17/20
- 💵 Valuation — 15/20
- ⚠️ Risk — 6/10
Summary:
📈 Growth & Financial Trajectory
Eight quarters show steady top-line expansion from about $4.12B in 2024-Q2 to roughly $5.20B in 2026-Q1, a gain of ~26%, while Net Income climbs from about $468M to $1.34B. Gross margins hold around 69-70%, with operating margin converging toward the mid- to high-teens and reaching about 21% by 2026-Q1, indicating improving operating leverage.
💰 Margins & Cash Flow
Gross margin remains robust (~69-70%). Operating margin trend improves in mid-2025 and stays strong into 2026-Q1. Net cash flow from operating activities is consistently positive, typically in the low-to-mid billions per quarter, while investing cash flow is negative and financing activity mixed, resulting in solid overall liquidity.
🛡️ Balance Sheet & Liquidity
Total assets run around $41-44B, with Equity in the $22-26B range. Liabilities are prudent relative to equity; debt load appears modest and coverage of operating cash flow is healthy, supporting liquidity.
⚠️ Key Drivers & Risks
- Drivers: Steady demand for cardiovascular devices; favorable margins and operating leverage.
- Risks: Medtech cyclicality and regulatory/reimbursement sensitivity; valuation is sensitive to growth pace and macro conditions.